Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.80 -2.0%	$17.69	$13.53 ▼ $35.25	$1.69B	2.09	1.49 million shs	4.49 million shs
CNTA Centessa Pharmaceuticals	$13.13 +0.7%	$12.83	$8.46 ▼ $19.09	$1.75B	1.48	731,873 shs	817,525 shs
CRMD CorMedix	$12.50 -16.4%	$12.21	$3.61 ▼ $17.43	$847.75M	1.62	1.31 million shs	9.88 million shs
GLPG Galapagos	$27.98 -0.3%	$27.57	$22.36 ▼ $31.23	N/A	0.07	250,589 shs	183,086 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+0.24%	+6.73%	-13.98%	-28.30%
CNTA Centessa Pharmaceuticals	0.00%	+5.63%	-0.08%	-8.69%	+45.40%
CRMD CorMedix	0.00%	-8.16%	+3.56%	+102.92%	+188.68%
GLPG Galapagos	0.00%	+2.04%	-3.58%	+11.39%	+12.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.3103 of 5 stars	3.5	1.0	2.2	2.5	0.6
CNTA Centessa Pharmaceuticals	3.095 of 5 stars	3.5	3.0	1.9	3.3	0.6
CRMD CorMedix	1.6062 of 5 stars	3.6	1.0	2.0	0.0	0.6
GLPG Galapagos	0.3574 of 5 stars	0.8	3.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	190.18% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	112.41% Upside
CRMD CorMedix	3.17	Buy	$16.67	33.33% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-9.46% Downside

Current Analyst Ratings Breakdown

Latest CRMD, GLPG, BEAM, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/7/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $15.00
5/6/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.60	N/A	N/A	$8.86 per share	1.90
CNTA Centessa Pharmaceuticals	$6.85M	255.99	N/A	N/A	$3.05 per share	4.30
CRMD CorMedix	$43.47M	19.50	N/A	N/A	$1.40 per share	8.93
GLPG Galapagos	$298.31M	N/A	$0.73 per share	38.54	$47.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
CRMD CorMedix	-$17.93M	$0.22	56.82	13.30	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)

Latest CRMD, GLPG, BEAM, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
CRMD CorMedix	N/A	4.21	3.99
GLPG Galapagos	N/A	7.95	7.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CNTA Centessa Pharmaceuticals	82.01%
CRMD CorMedix	34.18%
GLPG Galapagos	32.46%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
CNTA Centessa Pharmaceuticals	7.09%
CRMD CorMedix	5.30%
GLPG Galapagos	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable

CRMD, GLPG, BEAM, and CNTA Headlines

Recent News About These Companies

Galapagos N.V. ADR Advanced Charts | GLPG | Barron's

June 29 at 6:49 PM | barrons.com

Galapagos NV ADR Analysis & Opinion (GLPG) - Investing.com

June 28 at 10:26 AM | investing.com

Notable Two Hundred Day Moving Average Cross - GLPG

June 25, 2025 | nasdaq.com

Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer

June 23, 2025 | finanznachrichten.de

Galapagos Appoints Aaron Cox as Chief Financial Officer

June 23, 2025 | globenewswire.com

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity ...

June 20, 2025 | manilatimes.netM

Galapagos Unveils Promising Results for GLPG5101 at ICML 2025

June 20, 2025 | tipranks.com

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

June 18, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/18/3101896/0/en/galapagos-presented-new-data-at-icml-2025-from-cohort-3-of-atalanta-1-in-relapsed-refractory-indolent-nhl-patients-demonstrating-high-complete-response-and-mrd-negativity-rates-wit.html$

Owning 37% shares,institutional owners seem interested in Galapagos NV (AMS:GLPG),

June 17, 2025 | uk.finance.yahoo.com

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

June 12, 2025 | globenewswire.com

Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Reduce" by Brokerages

June 12, 2025 | marketbeat.com

Galapagos NV (NASDAQ:GLPG) Shares Sold by Millennium Management LLC

June 5, 2025 | marketbeat.com

Ameriprise Financial Inc. Decreases Holdings in Galapagos NV (NASDAQ:GLPG)

June 1, 2025 | marketbeat.com

Delivering CAR T-Cell Therapies Faster Than Ever Before

May 30, 2025 | usatoday.com

Wealthedge Investment Advisors LLC Acquires New Holdings in Galapagos NV (NASDAQ:GLPG)

May 30, 2025 | marketbeat.com

Galapagos NV: Galapagos Creates New Subscription Right Plan

May 27, 2025 | finanznachrichten.de

Galapagos Creates New Subscription Right Plan

May 27, 2025 | globenewswire.com

Galapagos Reaches Analyst Target Price

May 22, 2025 | nasdaq.com

Galapagos Announces Oral Presentations at EHA and…

May 20, 2025 | pharmiweb.comP

Galapagos to reevaluate spinoff plans; names new CEO

May 13, 2025 | msn.com

Galapagos halts corporate separation, explores strategic alternatives; shares rise

May 13, 2025 | ca.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, GLPG, BEAM, and CNTA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.80 -0.34 (-1.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$17.21 +0.41 (+2.46%)

As of 04:57 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.13 +0.09 (+0.69%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.32 +0.19 (+1.45%)

As of 04:00 AM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

CorMedix NASDAQ:CRMD

$12.50 -2.46 (-16.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.60 +0.11 (+0.84%)

As of 04:58 AM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Galapagos NASDAQ:GLPG

$27.98 -0.09 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$28.02 +0.04 (+0.13%)

As of 04:00 AM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time